Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Receptor Serine/Threonine Kinase | NCIT_C29921 | [Encoded by Receptor Serine/Threonine Kinase Genes, Receptor Serine/Threonine Kinases bind to specific signaling factors causing a conformational and functional change in the ligand-bound receptor, altering its interaction with target molecules, increasing the receptor kinase activity, and leading to changes in cellular physiology through modification of the activity of one or more signal transduction pathways.] |
| Metallopeptidase Gene | NCIT_C21275 | [A gene that encodes a proteolytic enzyme that depends on a metal ion to catalyze peptide bond hydrolysis.] |
| Proteolysis | NCIT_C18105 | [Proteolysis typically involves hydrolysis of specific peptide bond(s) with formation of smaller polypeptides in a target protein during maturation or modification of functional activity. The process may be catalyzed by proteolytic enzymes, by acids, or by bases.] |
| ADAMTS1 Gene | NCIT_C21276 | [This gene is involved in the inhibition of angiogenesis and cell proliferation.] |
| A Disintegrin and Metalloprotease with Thrombospondin Motifs 1 | NCIT_C21277 | [A disintegrin and metalloproteinase with thrombospondin motifs 1 (967 aa, ~105 kDa) is encoded by the human ADAMTS1 gene. This protein plays a role in both proteolysis and integrin-mediated signaling.] |
| Colorectal Cancer pTX TNM Finding v6 and v7 | NCIT_C60839 | [Colorectal cancer in which the primary tumor cannot be assessed. (from AJCC 6th and 7th Eds.)] |
| Ontology | NCIT_C21270 | [In information science, an explicit formal specification of how to represent the objects, concepts and other entities that are assumed to exist in some area of interest and the relationships among them.] |
| Terminology Entity | NCIT_C42698 | [Terminology entities represent the elements that form and define an ontology.] |
| ACVR2A Gene | NCIT_C21271 | [This gene plays a role in the transforming growth factor-beta signal transduction pathway through constitutive kinase activity.] |
| Activin Receptor Type-2A | NCIT_C21272 | [Activin receptor type-2A (513 aa, ~58 kDa) is encoded by the human ACVR2A gene. This protein is involved in signal transduction and embryonic development.] |
| ACVR2B Gene | NCIT_C21273 | [This gene plays a role in the transforming growth factor-beta signal transduction pathway and is essential for ligand binding and kinase activity.] |
| Pattern Formation | NCIT_C19970 | [Pattern Formation is a developmental morphogenetic process that establishes basic configurations of cellular organization necessary for further and accurate development of the spatial arrangements of embryonic tissue.] |
| Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3 | NCIT_C131825 | [A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.] |
| Immunostimulant | NCIT_C2139 | [Substances that stimulate the immune system.] |
| VDAC/HK2 Modulator Ointment VDA-110 | NCIT_C131826 | [A topical ointment formulation containing a voltage-dependent anion channel (VDAC)/hexokinase 2 (HK2) modulator, with potential activity against certain skin cancers. Upon topical application, VDA-1102, as a protein-protein interaction (PPI) disrupter, allosterically binds to HK2, and causes HK2 to dissociate from VDAC, which prevents glycolysis and triggers apoptosis, thereby inhibiting tumor cell growth in VDAC/HK2-expressing tumor cells without affecting the surrounding healthy skin tissue. The VDAC/HK2 system, over-activated in cancer cells, plays a key role in tumor cell proliferation. The VDAC/HK2 association protects cancer cells from apoptosis. HK2 is overexpressed in many malignant cancer tissues that rely on glycolysis, while its expression is limited in normal healthy cells.] |
| Chemotherapeutic Topical Agent | NCIT_C2252 | [An agent applied topically that inhibits the maturation, growth or spread of tumor cells.] |
| LSD1 Inhibitor IMG-7289 | NCIT_C131827 | [An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, IMG-7289 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.] |
| Anti-CD133-PE38-KDEL Fusion Protein | NCIT_C131828 | [A fusion protein consisting of an anti-single-chain variable fragment (scFv) peptide sequence targeting the extracellular domain of human CD133 (prominin-1) (anti-CD133scFV) and a deimmunized truncated form of Pseudomonas exotoxin A (38-kDa derivative of PE; PE38) where the five C-terminal amino acid residues have been replaced with the endoplasmic reticulum (ER) retention signal, KDEL, with potential antineoplastic activity. Upon administration of the anti-CD133-PE38-KDEL fusion protein, the anti-CD133 scFV moiety targets and binds to CD133, which is expressed on a variety of tumor cells. Upon internalization of the receptor-fusion protein complex, the KDEL sequence targets the fusion protein to the ER, where the PE38 exotoxin portion then inhibits protein synthesis, which results in a reduction of proliferation of CD133-expressing tumor cells. CD133, a glycoprotein expressed by a variety of cancers and especially by cancer stem cells (CSCs), plays a key role in tumor initiation, proliferation and progression.] |
| Antineoplastic Biological Agent | NCIT_C129821 | [Any agent that has a biological nature, such as agents containing living organisms, derived from living organisms, or comprised of ex vivo synthesized analogs of substances derived from living organisms, and that exerts antineoplastic activity.] |
| St. George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients | NCIT_C106890 | [A standardized rating scale developed by Jones et al in 1992, which is a shorter version derived from the original SGRQ, and used to measure health impairment and perceived well-being (quality of life) in patients with asthma and chronic obstructive pulmonary disease (COPD). It has also been used in patients with bronchiectasis, post tuberculosis, kyphoscoliosis and sarcoidosis. The questionnaire contains 2 parts of 14 questions. Part 1 comprises questions 1 to 7 and addresses the frequency of a subject's respiratory symptoms. Part 2 has questions 8 to 14 and addresses the patient's current state.] |